Precemtabart tocentecan

Precemtabart tocentecan is an antibody-drug conjugate developed by EMD Serono Research & Development Institute. Its target is CEACAM5 (the sponsor names CEACAM5). The sponsor states: An antibody-drug conjugate against CEACAM5 carrying an exatecan (topoisomerase inhibitor) payload, given intravenously once every three weeks. ClinicalTrials.gov describes the intervention as: Precem-TcT, administered, once every 3 weeks intravenously, on Day 1 of each 21-day cycle. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, including the phase 3 study NCT07549412 (A Study of Precemtabart Tocentecan With or Without Bevacizumab Compared to Trifluridine/Tipiracil Plus Bevacizumab in Participants With Previously Treated Metastatic Colorectal Cancer (PROCEADE-CRC-03)), in colorectal cancer. The largest, NCT07549412, plans to enrol 1020 participants with primary completion expected 2029-10-16. Status reflects the highest phase registered on ClinicalTrials.gov at the 2026-09-11 check; no efficacy results are recorded here.